Alzheimer’s disease drug subcutaneous injection approved in the US
September 2, 2025
Source: drugdu
103
On August 29th local time, Japan's Eisai Co., Ltd. and the US Biogen Inc. announced that the US FDA (U.S. Food and Drug Administration) has approved the weekly maintenance dose of lencanelumab subcutaneous automatic injection (SC-AI) for the treatment of early Alzheimer's disease (AD).
Comment: As of now, there are limited AD treatment drugs approved worldwide. This approval makes Lencaneluzumab the first AD treatment drug that can be administered subcutaneously at home using an automatic injector. The entire injection process takes an average of only 15 seconds, which further consolidates the company's market position in this field.
https://finance.eastmoney.com/a/202509013500390220.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
